AstraZeneca | Investor Event Presentation Deck | 42 slides · page 29 of 42
The slide summarizes the primary outcomes of the SERENA-2 trial, confirming PFS benefits and safety, and mentions ongoing Phase III trials (SERENA-4 and SERENA-6).
Conference presentation · key_takeaways · summarize · dense density
Slide locked Sign in to view
Slide schematic 4/4
callout 1/1 list 1/1 source-note 1/1 title 1/1
Components 4
primary bullet source-note headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.